Board of Directors
Charles Kummeth was appointed Chair of the board of directors in May 2024 and has over 35 years of leadership experience in life sciences, most recently as President and CEO of Bio-Techne, a life sciences manufacturing company that develops and sells life science reagents and instruments., a position he held from April 2013 to February 2024. Prior to Bio-Techne, from August 2011 to March 2013, Mr. Kummeth served in roles as President of Mass Spectrometry and Chromatography and President of the Laboratory Consumables Division, both at Thermo Fisher Scientific Inc., a global leader in delivering technology, pharmaceutical and biotechnology services Prior to joining Thermo Fisher, Mr. Kummeth served in various roles during his 24-year career at 3M Corporation, a manufacturing company, culminating as the Vice President of the company’s Medical Division.
Mr. Kummeth also currently serves on the board of directors of Gentherm Incorporated, PerkinElmer, Inc. and Orthofix Medical, Inc. Mr. Kummeth received a B.S. in electrical engineering from the University of North Dakota, and a M.S. in computer science from the University of St. Thomas and an MBS from the Carlson School of Business at the University of Minnesota. Mr. Kummeth’s qualifications to serve on our board of directors include his 35 years of leadership roles in the life sciences space, including extensive experience of growing early-stage life science companies.
Jonathan M. Rothberg, Ph.D. is the founder of our predecessor entity and has served on our board of directors since the closing of the business combination in June 2021. He was appointed Chairman of the Board in June 2021 and served in this role until May 2024 when Mr. Kummeth was appointed as Chairman but continues to serve as a member of the Board. Dr. Rothberg also served as our Interim Chief Executive Officer from February 2022 to October 2022. Dr. Rothberg had served as the Executive Chairman of our predecessor entity since December 2015 and as the Chief Executive Officer from December 2015 to November 2020. Dr. Rothberg is the founder of the 4Catalyzer medical technology incubator and the founder of each of its companies: Quantum-Si, AI Therapeutics, Inc. (formerly LAM Therapeutics, Inc.), Butterfly Network, Inc., Detect, Inc. (formerly Homodeus Inc.), Hyperfine, Inc., identifeye Health Inc. (formerly Tesseract Health, Inc.), Liminal Sciences, Inc. (formerly EpilepsyCo Inc.), and Protein Evolution, Inc.
Additionally, Dr. Rothberg has served as an Adjunct Professor of Research of Genetics at Yale School of Medicine since July 2015. Dr. Rothberg previously founded and served as Chairman, Chief Executive Officer, and Chief Technology Officer of Ion Torrent Systems, Inc. from 2007 to 2010, and founded and served as Chairman and Chief Executive Officer of RainDance Technologies, Inc. from 2004 to 2009. From 1999 to 2007, Dr. Rothberg co-founded and served as Chairman of ClarifI, Inc., and from 1999 to 2006, he founded and served as Chairman, Chief Executive Officer and Chief Technology Officer of 454 Life Sciences Corporation, a biotechnology company. Prior to 454 Life Sciences Corporation, Dr. Rothberg founded and served as Chairman and Chief Executive Officer of CuraGen Corporation, a biopharmaceutical development company, from 1993 to 2004. From March 2014 to April 2020, Dr. Rothberg served as Interim Chief Executive Officer of Butterfly Network, Inc. and currently serves on the board of directors of Butterfly Network, Inc. He also served as the Chief Executive Officer of the legacy Company of Hyperfine, Inc., a health technology company, from 2014 to 2021 and currently serves on the board of directors of Hyperfine, Inc.
Dr. Rothberg received his Ph.D., M. Phil. and M.S. in biology from Yale University and his B.S. in chemical engineering from Carnegie Mellon University. Dr. Rothberg’s qualifications to serve on our board of directors include his significant scientific, executive and board leadership experience in the technology industry, as well as his knowledge of our business as our predecessor entity’s founder.
Paula Dowdy has served on our board of directors since March 2024. Ms. Dowdy has over 35 years of global commercial and operational experience. From August 2016 to January 2023, Ms. Dowdy held the position of Senior Vice President and General Manager for Europe, Middle East and Africa at Illumina, Inc. Ms. Dowdy also spent over 20 years at Cisco Systems, Inc., a digital communications technology company, and held various global positions of increasing responsibility in products, services, and software, most recently as Senior Vice President.
Ms. Dowdy also currently serves on the board of directors of Aptitude Software Limited. Ms. Dowdy holds a B.A. in history from University of California, Berkeley and an M.B.A. in business from Pepperdine University. Ms. Dowdy’s qualifications to serve on our board of directors include her extensive experience in leadership roles at other biotechnology and technology companies.
Ruth Fattori has served on our board of directors since the closing of the business combination in June 2021 and had served on our predecessor entity’s board of directors since March 2021. Since January 2019, Ms. Fattori has served as the Managing Director of Pecksland Partners, a consulting firm dedicated to advising boards of directors, CEOs and senior executives on human resources issues. Beginning January 2019, she has also served as a Senior Advisor at the Boston Consulting Group, a consulting group, supporting its CEO Advisory program and People & Organization Practice. From February 2013 through December 2018, Ms. Fattori served in various roles at PepsiCo, Inc., a food and beverage company, most recently as Executive Vice President and Chief Human Resources Officer. From 2010 to February 2013, she served as Managing Partner of Pecksland Partners, an advisory group, and from 2008 to 2009 she was Executive Vice President and Chief Administrative Officer for MetLife, Inc., a global insurance provider. Earlier in her career, she was the Executive Vice President and Chief Human Resources Officer at Motorola, Inc., a telecommunications company.
Ms. Fattori also currently serves on the board of directors of Hyperfine, Inc., a health technology company. She holds a B.S. in mechanical engineering from Cornell University. Ms. Fattori’s qualifications to serve on our board of directors include her extensive executive and human resources management experience.
Jeffrey Hawkins has served as our President and Chief Executive Officer and as a member of our board of directors since October 2022. He previously served as President and Chief Executive Officer of Truvian Sciences, Inc., a biotechnology company focused on blood testing, from January 2018 to July 2022 and as a technical advisor from August 2022 to September 2022. Prior to Truvian Sciences, from October 2015 to January 2018, Mr. Hawkins served as Vice President and General Manager, Reproductive and Genetic Health at Illumina, Inc., a biotechnology company focused on genomics and human health. From December 2009 to October 2015, he held senior leadership positions at GenMark Diagnostics, Inc., a syndromic molecular diagnostics company focused on infectious disease, including most recently as Senior Vice President, Global Marketing and Program Management. Earlier in his career, Mr. Hawkins served in various executive director, executive marketing and business development roles at Hologic, Inc., a developer, manufacturer and supplier of medical imaging systems and diagnostic and surgical product; Osmetech Technology, Inc., a molecular diagnostics provider; and Third Wave Technologies Inc., a provider of DNA and RNA analysis products to clinical, research and agricultural customers. He also held positions of increasing responsibility in marketing, product development, and operations at Abbott Laboratories, a medical devices and technologies provider, and Sysmex America, Inc., a medical diagnostic solutions provider.
Mr. Hawkins holds a B.A. in chemistry from Concordia University and an M.B.A. from Keller Graduate School of Management. Mr. Hawkins’ qualifications to serve on our board of directors include his extensive executive leadership experience and his background in the life sciences industry, including in the genetic health industry.
Amir Jafri has served on our board of directors since September 2023. Mr. Jafri is the founder of Immunicom, Inc., a privately held clinical-stage biotechnology company, and has served as its President and Chief Executive Officer since its inception in 2013. Previously, Mr. Jafri served as Chief Operating Officer at West Health Institute, a nonprofit healthcare organization, from February 2010 to January 2011. Prior to West Health, Mr. Jafri was VP/CTO, VP R&D and VP Operations at Cardinal Health, a healthcare services and products company, from 2003 to 2010. From 2001 to 2003, he served as VP/General Manager of the healthcare technology practice of the Comsys division of ManpowerGroup, a workplace solutions company. Prior to that, Mr. Jafri founded various healthcare startups that were subsequently acquired.
Mr. Jafri received his B.Sc. from Houston Christian University with a double major in chemistry and biology and a minor in history. Mr. Jafri’s qualifications to serve on our board of directors include his operational experience as a founder, executive and director in the healthcare and medical device industries.
John Patrick (“Jack”) Kenny has served on our board of directors since May 2023. Mr. Kenny has over 30 years of operational and commercial leadership experience. Mr. Kenny served as the Chief Executive Officer and was a member of the board of directors of Meridian Bioscience Inc.’s (“Meridian”), a diagnostic products company, from October 2017 to June 2023. Prior to his role at Meridian, Mr. Kenny served as Senior Vice President and General Manager, North America, of Siemens Healthcare, a medical technology and imaging company, from October 2014 to May 2017. From 2012 to 2014, Mr. Kenny served as Vice President and General Manager, U.S. Region, for Becton Dickinson, a medical technology company. Prior to 2012, he held executive roles at Danaher Corporation, a life sciences and diagnostics company, and Quest Diagnostics, a diagnostic information services provider.
Mr. Kenny has served on the board of directors of OraSure Technologies, Inc. since September 2024 and NeoGenomics, Inc. since December 2025. Mr. Kenny holds his B.S. in management systems from Kettering University. Mr. Kenny’s qualifications to serve on our board of directors include his operational experience as the Chief Executive Officer of a publicly traded company, along with his executive leadership in the healthcare and medical device industries.
Brigid A. Makes has served on our board of directors since June 2021. Ms. Makes served as Chief Financial Officer of Vivani Medical Inc., a Nasdaq listed pharmaceutical company (VANI) from August 2022 through August 2025. Vivani merged with Nano Precision Medical Inc., a private bio pharmaceutical company, where Ms. Makes served as a part-time Chief Financial Officer. Ms. Makes has served as an independent consultant for medical device and healthcare companies since July 2017, specifically advising on financial, funding and strategic responsibilities. From September 2011 to July 2017, Ms. Makes served as Senior Vice President and Chief Financial Officer of Miramar Labs, Inc., a biotechnology company focused on aesthetics and dermatology. From 2006 to 2011, Ms. Makes served as Senior Vice President and Chief Financial Officer of AGA Medical Corporation, a medical device company developing interventional devices for the minimally invasive treatment of structural heart defects and peripheral vascular disorders. Prior to joining AGA, Ms. Makes held various positions at Nektar Therapeutics Inc., a biopharmaceutical company, from 1999 to 2006, including serving as Chief Financial Officer. Prior to 1999, Ms. Makes also served as Chief Financial Officer at Oravax Inc., a vaccine company, and Haemonetics Corporation, a provider of blood and plasma supplies and services.
Ms. Makes also currently serves on the board of directors of Elutia Inc. (formerly Aziyo Biologics). Ms. Makes holds an M.B.A. in finance from Bentley University and a Bachelor of Commerce degree in finance & international business from McGill University. Ms. Makes’ qualifications to serve on our board of directors include her extensive executive leadership experience in the healthcare and life sciences industries, her significant corporate finance experience, and her experience serving on the board of directors of other publicly traded companies.
Scott Mendel has served on our board of directors since May 2023. Mr. Mendel has over 30 years of financial and operational leadership experience. Mr. Mendel previously served in roles of increasing responsibility at GenMark Diagnostics, Inc., a syndromic molecular diagnostics company focused on infectious disease (acquired by Roche in April 2021), including as Chief Executive Officer from February 2020 to September 2021, as Chief Operating Officer from February 2019 to February 2020, and as Chief Financial Officer from May 2014 to February 2019. Prior to GenMark, Mr. Mendel served as Chief Financial Officer of The Active Network, Inc., a global software as a service company that provides technology to organizers of events and activities, from March 2010 through its acquisition by the private-equity firm Vista Equity Partners in December 2013. Prior to joining The Active Network, Inc., Mr. Mendel held various positions in finance at General Electric, a technology, media and financial services company, for over 20 years, including as Chief Financial Officer from March 2003 to March 2010 for General Electric’s Healthcare IT division.
Mr. Mendel also currently serves on the board of directors of Quanterix Corporation. Mr. Mendel holds a B.S. in finance from Indiana University and an M.B.A. in business from Northwestern University’s Kellogg School of Management. Mr. Mendel’s qualifications to serve on our board of directors include his significant experience in the diagnostics industry, extensive financial knowledge, and his experience serving in leadership roles at other publicly-traded companies.
Kevin Rakin has served on our board of directors since June 2020. Mr. Rakin was HighCape Capital Acquisition Corp’s Chief Executive Officer from June 2020 to June 2021. Since October 2013, Mr. Rakin has been a co-founder and partner of HighCape, a growth equity firm, and he brings more than 30 years of experience as an executive and investor in the life sciences industry. Previously, from June 2011 to November 2012, he served as the President of Shire Regenerative Medicine. From 2005, Mr. Rakin was the Chairman and Chief Executive Officer of Advanced BioHealing, Inc., a provider of regenerative medicine solutions until its sale to Shire, PLC in 2011. Before that, he served as an Executive-In-Residence at Canaan Partners, a venture capital firm until its merger with Clinical Data, Inc. in 2005. Mr. Rakin was also the co-founder, President and Chief Executive Officer of Genaissance Pharmaceuticals, Inc., a biotechnology company.
Mr. Rakin also currently serves on the board of directors of Brainstorm Cancer Therapeutics, Inc., CapeHaven Holding Company, LLC, CapeHaven, Inc., Elutia, Inc. (formerly Aziyo Biologics, Inc.) (Chairman), and Nyxoah S.A. Mr. Rakin previously served on the board of directors of Histogenics Corp., Oramed Pharmaceuticals, Inc. and Tela Bio Inc. Mr. Rakin holds an M.B.A. in business management from Columbia University and B.Com. (Hons) in finance and accounting from the University of Cape Town, South Africa. Mr. Rakin’s qualifications to serve on our board of directors include his extensive experience in the life sciences industry, as both an executive and an investor and his network of contacts in the industry.